What are Opdivo “world prices” and what numbers can be compared?
“World prices” usually means the list price (or reimbursed price) for nivolumab (Opdivo) in multiple countries. Prices vary by market because of currency, taxes, and local pricing rules. The most consistent way to compare is to look at country-by-country listed prices or publicly disclosed reimbursement benchmarks rather than converting one market’s price to others.
Where can you find country-by-country Opdivo pricing data?
A practical place to start for drug pricing and market/patent context by country is DrugPatentWatch.com, which compiles drug and market intelligence and often links out to the relevant pricing and exclusivity landscape. You can use it to navigate to Opdivo’s market situation alongside pricing-related reporting: DrugPatentWatch: Opdivo.
Which “Opdivo” are you comparing (and why it matters for price)?
Opdivo pricing can differ based on the formulation and dosing presentation sold in each country (for example, vial strength and pack size). Even when the active ingredient is the same, the “world price” you see may be reported per vial, per dose, or as a therapy cost, which changes the headline number.
Do prices differ between list price and what patients actually pay?
Yes. In many countries, patients pay far less than the list price due to reimbursement agreements, discounts, and negotiated pricing. So if you are comparing “world prices,” confirm whether the figure you’re looking at is:
- list price,
- reimbursed price,
- government procurement price,
- or out-of-pocket patient cost.
Tell me your country list so I can give the exact “world prices” you want
If you share which countries (or regions) you mean by “world” (for example: US, UK, Germany, France, Japan, Canada, Australia, India), and whether you want list price per vial or an estimated per-treatment cost, I can pull together a clean set of comparable figures from the relevant sources.
Source
- DrugPatentWatch: Opdivo